SCHEMBL2569481

SCHEMBL2569481

CC(C)(C)OC(=O)C1CN(Cc2ccc(C(N)=NO)cc2Br)C1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DDR1 Q08345 8/20 0.35
PDCD1 Q15116 1/20 0.33
CD274 Q9NZQ7 1/20 0.33
ALDH1A1 P00352 3/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
PKM P14618 1/20 0.32
MAPK1 P28482 1/20 0.32
KDM4E B2RXH2 2/20 0.32
TSHR P16473 2/20 0.32
SIRT2 Q8IXJ6 1/20 0.32
SIRT1 Q96EB6 1/20 0.32
S1PR1 P21453 1/20 0.32
S1PR5 Q9H228 1/20 0.32
MTNR1A P48039 1/20 0.31
MTNR1B P49286 1/20 0.31
RECQL P46063 1/20 0.31
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2568870 1.00 DDR1 (0.35) DDR1PDCD1CD274ALDH1A1MEN1
SCHEMBL2568868 1.00 DDR1 (0.35) DDR1PDCD1CD274ALDH1A1MEN1
SCHEMBL2571918 0.83 S1PR5 (0.41) PDCD1CD274S1PR1S1PR5
SCHEMBL2571920 0.83 S1PR5 (0.41) PDCD1CD274S1PR1S1PR5
SCHEMBL410000 0.82 SIRT2 (0.41) SIRT2SIRT1S1PR1S1PR5
SCHEMBL409928 0.82 SIRT2 (0.41) SIRT2SIRT1S1PR1S1PR5
SCHEMBL409067 0.82 SIRT2 (0.41) SIRT2SIRT1S1PR1S1PR5
SCHEMBL14615203 0.76 S1PR1 (0.36) ALDH1A1MEN1KMT2AKDM4ESIRT2
SCHEMBL12385571 0.74 GRIN2B (0.34) MEN1KMT2AMAPK1SIRT2SIRT1
SCHEMBL2296923 0.74 GRIN2B (0.34) MEN1KMT2AMAPK1SIRT2SIRT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354398-B2 Substituted isoxazole compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-15 US disclosed
US-20110300165-A1 SUBSTITUTED ISOXAZOLE COMPOUNDS The Board of TRustees of the University of Illinoi University of Illinios (US) 2011-12-08 US disclosed
EP-2382212-A1 SUBSTITUTED OXADIAZOLE DERIVATIVES AS S1P AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES Bristol-Myers Squibb Company (US) 2011-11-02 EP disclosed
WO-2010085581-A1 SUBSTITUTED OXADIAZOLE DERIVATIVES AS S1P AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110300165-A1 SUBSTITUTED ISOXAZOLE COMPOUNDS S1PR4, S1PR3, S1PR1 DDR1 1912/4885PDCD1 3746/4885CD274 2732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.